| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 1/100-1/200 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | Tyrosine kinase-type cell surface receptor HER3 |
| Entrez GeneID | 2065; |
| WB Predicted band size | 185kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Peptide sequence around aa.1287~1291 (Q-G-Y-E-E) derived from Human Her3/ErbB3. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是关于Her3/ErbB3 (Ab-1289)抗体的3篇参考文献示例：
1. **文献名称**：*"ErbB3/HER3 intracellular domain is essential for PI3K/Akt signaling activation in cancer cells"*
**作者**：Smith A, et al.
**摘要**：该研究利用Ab-1289抗体通过Western blot和免疫沉淀技术，证明Her3的胞内结构域在激活PI3K/Akt信号通路中的关键作用，并发现其在乳腺癌细胞中促进肿瘤存活。
2. **文献名称**：*"Targeting HER3 to overcome resistance in EGFR-mutated non-small cell lung cancer"*
**作者**：Chen L, et al.
**摘要**：研究通过免疫组化(使用Ab-1289抗体)证实Her3在EGFR抑制剂耐药的非小细胞肺癌中高表达，并验证其作为联合治疗靶点的潜力。
3. **文献名称**：*"HER2-HER3 heterodimerization contributes to trastuzumab resistance in HER2+ breast cancer"*
**作者**：Wang Y, et al.
**摘要**：该文献利用Ab-1289抗体进行共免疫沉淀实验，揭示Her2/Her3异源二聚体形成与曲妥珠单抗耐药性的关联，并提出阻断Her3可增强治疗效果。
注：以上文献为示例性质，具体内容需根据实际发表论文调整。建议通过PubMed或学术数据库以“Her3/ErbB3 antibody Ab-1289”为关键词检索真实文献。
The Her3/ErbB3 (Ab-1289) antibody is a specific reagent designed to detect human ErbB3 (HER3), a member of the epidermal growth factor receptor (EGFR) family. Unlike EGFR or HER2. HER3 lacks intrinsic kinase activity but activates downstream signaling pathways, such as PI3K/Akt, through heterodimerization with other EGFR members. This receptor is implicated in cancer progression, drug resistance, and metastasis, particularly in HER2-positive and EGFR-driven tumors. The Ab-1289 antibody typically recognizes HER3 phosphorylated at specific tyrosine residues (e.g., Tyr1289), a key site linked to receptor activation and oncogenic signaling.
Developed for research applications like Western blotting, immunohistochemistry (IHC), and immunoprecipitation (IP), this antibody aids in studying HER3 expression, activation status, and its role in therapeutic resistance. Its specificity for phosphorylated HER3 makes it valuable for investigating ligand-induced signaling (e.g., neuregulin binding) or compensatory HER3 upregulation following targeted therapies. Researchers employ Ab-1289 in preclinical models and clinical samples to explore HER3’s contribution to malignancies, including breast, gastric, and colorectal cancers. By elucidating HER3 dynamics, this tool supports the development of HER3-targeted therapies, such as monoclonal antibodies or kinase inhibitors, aiming to overcome resistance to EGFR/HER2-directed treatments.
×
